Association strongest for B-cell precursor acute lymphoblastic leukemia
THURSDAY, March 28, 2024 (HealthDay News) — Exclusive breastfeeding duration of at least three months may decrease the risk for childhood hematologic cancers, according to a study published online March 26 in JAMA Network Open.
Signe Holst Søegaard, Ph.D., from the Danish Cancer Society in Copenhagen, and colleagues investigated whether longer duration of exclusive breastfeeding is associated with a decreased risk for childhood acute lymphoblastic leukemia (ALL) and other childhood cancers. The analysis included administrative data for 309,473 children born between January 2005 and December 2018, identified from the Danish National Child Health Register.
The researchers found that compared with exclusive breastfeeding duration of less than three months, exclusive breastfeeding for at least three months was associated with a decreased risk for hematologic cancers (adjusted hazard ratio [aHR], 0.66; 95 percent confidence interval [CI], 0.46 to 0.95), which was largely attributable to a decreased risk for B-cell precursor ALL (BCP-ALL; aHR, 0.62; 95 percent CI, 0.39 to 0.99). There were no associations between breastfeeding duration and risk for central nervous system tumors (aHR, 0.96; 95 percent CI, 0.51 to 1.88) or solid tumors (aHR, 0.87; 95 percent CI, 0.55 to 1.41).
“This finding is consistent with emerging investigations implicating early gut microbiome maturation in childhood BCP-ALL pathogenesis,” the authors write. “To inform future preemptive interventions, additional studies should investigate the biologic mechanisms underlying the observed association.”
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors
Aircrew Face Higher Odds of Radiation-Related Cancer Deaths
Couples" Coping Skills Help Reduce Depression in GI Cancer Survivors
Genomic Newborn Screening Could ID Cancer Predisposition Syndrome
Patient Education Increases Skin Cancer Screening in Stem Cell Transplant Survivors
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Subclinical Cardiac Dysfunction Linked to Neurodegeneration in APOE-ε4 Carriers
Study IDs Gaps in Hereditary Breast Cancer Risk Assessment Before Gender-Affirming Mastectomy